Consistent with clinical trials, studies in murine tumor models have also demonstrated a correlation between tumor antigen-specific CD8+ T cell activation, reductions in tumor burden, and prolongation of overall survival[5, 8–11]. The gene discussed is CD8A; the disease is neoplasm.